John A Bostrom1, Beth Mottel1, Sean P Heffron2. 1. Department of Medicine, Leon H. Charney Division of Cardiology, NYU Center for the Prevention of Cardiovascular Disease, Cardiovascular Research Center, New York, NY, USA. 2. Department of Medicine, Leon H. Charney Division of Cardiology, NYU Center for the Prevention of Cardiovascular Disease, Cardiovascular Research Center, New York, NY, USA. sean.heffron@nyulangone.org.
Abstract
PURPOSE OF REVIEW: This study aims to discuss the mechanisms by which GLP-1 agonists and bariatric surgery improve cardiovascular outcomes in severely obese patients. RECENT FINDINGS: Recent studies have demonstrated that both GLP-1 agonist use and bariatric surgery reduce adverse cardiovascular outcomes. Improvements in traditional atherosclerosis risk factors in association with weight loss likely contribute, but weight loss-independent mechanisms are also suggested to have roles. We review the clinical and preclinical evidence base for cardiovascular benefit of LP-1 agonists and bariatric surgery beyond traditional risk factors, including improvements in endothelial function, direct impacts on atherosclerotic plaques, and anti-inflammatory effects.
PURPOSE OF REVIEW: This study aims to discuss the mechanisms by which GLP-1 agonists and bariatric surgery improve cardiovascular outcomes in severely obesepatients. RECENT FINDINGS: Recent studies have demonstrated that both GLP-1 agonist use and bariatric surgery reduce adverse cardiovascular outcomes. Improvements in traditional atherosclerosis risk factors in association with weight loss likely contribute, but weight loss-independent mechanisms are also suggested to have roles. We review the clinical and preclinical evidence base for cardiovascular benefit of LP-1 agonists and bariatric surgery beyond traditional risk factors, including improvements in endothelial function, direct impacts on atherosclerotic plaques, and anti-inflammatory effects.
Authors: Lars Sjöström; Markku Peltonen; Peter Jacobson; C David Sjöström; Kristjan Karason; Hans Wedel; Sofie Ahlin; Åsa Anveden; Calle Bengtsson; Gerd Bergmark; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Kristina Narbro; Ingmar Näslund; Torsten Olbers; Per-Arne Svensson; Lena M S Carlsson Journal: JAMA Date: 2012-01-04 Impact factor: 56.272
Authors: Elena Osto; Petia Doytcheva; Caroline Corteville; Marco Bueter; Claudia Dörig; Simona Stivala; Helena Buhmann; Sophie Colin; Lucia Rohrer; Reda Hasballa; Anne Tailleux; Christian Wolfrum; Francesco Tona; Jasmin Manz; Diana Vetter; Kerstin Spliethoff; Paul M Vanhoutte; Ulf Landmesser; Francois Pattou; Bart Staels; Christian M Matter; Thomas A Lutz; Thomas F Lüscher Journal: Circulation Date: 2015-02-11 Impact factor: 29.690
Authors: Tracey Gaspari; Iresha Welungoda; Robert E Widdop; Richard W Simpson; Anthony E Dear Journal: Diab Vasc Dis Res Date: 2013-05-14 Impact factor: 3.291
Authors: Ali Aminian; Alexander Zajichek; David E Arterburn; Kathy E Wolski; Stacy A Brethauer; Philip R Schauer; Michael W Kattan; Steven E Nissen Journal: JAMA Date: 2019-10-01 Impact factor: 56.272
Authors: Charles Baum; Katherine Andino; Eric Wittbrodt; Shelley Stewart; Keith Szymanski; Robin Turpin Journal: Pharmacoeconomics Date: 2015-07 Impact factor: 4.981